|Expense Ratio (net)||1.32%|
|Morningstar Risk Rating||★★★★★|
|Last Cap Gain||0.00|
|Inception Date||Apr 1, 1998|
|Average for Category||N/A|
The ongoing Ebola epidemic has refocused the world's attention on biotechs, as the ZMapp serum, from San Diego's Mapp Biopharmaceutical, helped treat two American infectees earlier this year. That's not ...